BriaCell Therapeutics(NASDAQ) BCTXZ

Market CapN/A

Since IPO (2025)-86%

5 YearN/A

1 Year-14%

1 Month+111%

$0.19

-10.23%

-0.02Today

BriaCell Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.19	2026-09-03

BriaCell Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+57.64%	USD 0.12	2026-08-27
1 month	+110.79%	USD 0.09	2026-08-04
3 month	+138.36%	USD 0.08	2026-06-05
Year to date	-34.7%	USD 0.29	2025-12-31
1 year	-13.82%	USD 0.22	2025-09-03
Since inception	-85.53%	USD 1.31	2025-04-25

BriaCell Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$30.65M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Price

$0.19

Volume

21,144

Open

$0.19

Price

$0.19

Volume

21,144

Open

$0.19

Previous Close

$0.19

Daily Range

$0.18 - $0.25

52-Week Range

$0.06 - $0.52

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Price

$0.19

Volume

21,144

Open

$0.19

Previous Close

$0.19

Daily Range

$0.18 - $0.25

52-Week Range

$0.06 - $0.52

Estimated Earnings Date

N/A

BCTXZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BriaCell Therapeutics

BriaCell Therapeutics Corp. is a biotechnology company based in West Vancouver, Canada, focused on developing innovative immunotherapies for cancer treatment. The company is advancing its flagship compound, Bria-IMT, a whole-cell cancer vaccine currently in Phase I/IIa clinical trials, alongside other promising therapies.

Products and Services

Bria-IMT: A whole-cell cancer vaccine in clinical development
Bria-OTS: A personalized immunotherapy for advanced breast cancer
BriaDx: A diagnostic tool for determining patient HLA types

Growth Outlook

Bria-IMT is in Phase I/IIa trials, indicating progress towards commercialization
Collaboration with Incyte Corporation enhances research capabilities
Partnership with the National Cancer Institute supports preclinical development

Financial Highlights

Recent quarterly net income of -$7.2 million reflects ongoing R&D investments
Cash and short-term investments total approximately $22.8 million
Current ratio of 7.07 indicates strong liquidity position

BriaCell Therapeutics Corp. is dedicated to addressing significant unmet needs in cancer treatment through its innovative therapies. The company's focus on immuno-oncology positions it well within a rapidly evolving sector. With a robust pipeline and strategic collaborations, BriaCell aims to make substantial advancements in cancer care. The financial metrics indicate a strong liquidity position, which may support ongoing research and development efforts. Investors may find the company's commitment to innovation and its promising clinical developments noteworthy as it navigates the complexities of the biotechnology landscape.

AI Generated • Aug 23, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

West Vancouver, BC V7T 2X1, CA

BCTXZ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-147.92%

Return on Capital

-153.48%

Return on Assets

-113.23%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

21.14K

Avg. Volume

149.69K

Financials (TTM)

Gross Profit

-$26.59K

Operating Income

-$32.01M

EBITDA

-$31.48M

Operating Cash Flow

-$30.88M

Capital Expenditure

-$129.18K

Free Cash Flow

-$31.01M

Cash & ST Invst.

$22.80M

Total Debt

$0.00

BriaCell Therapeutics Performance Analysis

BriaCell Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2025-07-31	N/A
Q1	2025-10-31	N/A
Q2	2026-01-31	N/A
Q3	2026-04-30	N/A

BriaCell Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2025-07-31	73.9%
Q1	2025-10-31	-1.6%
Q2	2026-01-31	40.7%
Q3	2026-04-30	61.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$7.16M

-16.9%

EBITDA

-$7.17M

-16.4%

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Total Cash

$22.80M

+83.0%

Total Debt

$0.00

N/A

Accounts Receivable

$2.59M

+11.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.13%

N/A

Return on Invested Capital

-1.36%

N/A

Free Cash Flow

-$7.21M

-0.6%

Operating Cash Flow

-$7.08M

+1.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NKGNNKGen Biotech, Inc. Common Stock

NKGNNKGen Biotech, Inc. Common Stock$0.00-97.38%

NCELNewcelX Ltd.

NCELNewcelX Ltd.$3.35+0.00%

XRTXXORTX Therapeutics Inc.

XRTXXORTX Therapeutics Inc.$2.15+1.90%

ELABPMGC Holdings Inc.

ELABPMGC Holdings Inc.$5.23+2.75%

WINTWindtree Therapeutics, Inc.

WINTWindtree Therapeutics, Inc.$0.00+0.00%

VRAXVirax Biolabs Group Limited

VRAXVirax Biolabs Group Limited$2.56+0.59%

AIMDAinos, Inc.

AIMDAinos, Inc.$1.56-1.27%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$10.38+0.11%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$106.74+0.00%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$51.60-0.00%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$46.35+0.06%

NVDANvidia

NVDANvidia$228.45+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$72.03+0.03%

NOKNokia

NOKNokia$9.77-0.01%

Questions About BCTXZ

What is the current price of BriaCell Therapeutics?

BriaCell Therapeutics is trading at $0.19 per share.

What is the 52-week range for BriaCell Therapeutics?

Over the past 52 weeks, BriaCell Therapeutics has traded between $0.06 and $0.52.

How much debt does BriaCell Therapeutics have?

BriaCell Therapeutics total debt is unavailable.

How much cash does BriaCell Therapeutics have on hand?

BriaCell Therapeutics does not have cash on hand data available.

What is BriaCell Therapeutics’s dividend yield?

BriaCell Therapeutics does not currently have a dividend yield.

BriaCell Therapeutics(NASDAQ) BCTXZ

BriaCell Therapeutics Financials at a Glance

BCTXZ News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About BriaCell Therapeutics

BCTXZ Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

BriaCell Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BCTXZ

What is the current price of BriaCell Therapeutics?

What is the 52-week range for BriaCell Therapeutics?

How much debt does BriaCell Therapeutics have?

How much cash does BriaCell Therapeutics have on hand?

What is BriaCell Therapeutics’s dividend yield?

Premium Investing Services